Therapy Areas: Respiratory
InventisBio (Shanghai) signs 'Collaboration Agreement' with Betta Pharma
31 December 2018 -

China-based InventisBio (Shanghai) has signed a 'Collaboration Agreement' with China-based Betta Pharma, it was reported on Friday.

According to the contract, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong and Taiwan) to Betta Pharma and is to co-develop this drug in China. Betta Pharma will have the exclusive commercialisation rights for the D-0316 product in the country.

The product is a third-generation EGFR-T790M tyrosine kinase inhibitor discovered and developed independently by InventisBio. It is mainly utilised for the treatment of EGFR-mutant non-small cell lung cancer. The drug is presently in phase one clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio worth RMB230m. After the product is marketed commercially, Betta Pharma will pay various sales milestones and tiered royalties based on annual sales.

Login
Username:

Password:


Related Headlines

Roche's Tecentriq chemotherapy combination granted FDA approval for the initial treatment of adults with extensive-stage small cell lung cancer

US FDA grants Orphan Drug Designation to AstraZeneca's saracatinib for idiopathic pulmonary fibrosis

AstraZeneca granted ODD to saracatinib for IPF by US FDA

Inova Health System, Roswell Park Comprehensive Cancer Center Join Kiyatec Clinical Trial to Predict Patient Response to Cancer Drugs Prior to Treatment

Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate

Biodesix Presents VeriStrat Data Demonstrating Independent Prediction of Immunotherapy Outcomes for NSCLC Patients

European Commission Approves US Merck's Keytruda (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer

Neoviva Project Supporting the Development of myvacAwarded a EUR 5.2m Grant from Bpifrance's "Investments for the Future" Programme

Celgene Provides Update on Abraxane Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

Lilly's lung cancer drug Cyramza(R) (ramucirumab) meets primary endpoint in Phase 3 RELAY Trial

US FDA approves new generic valsartan for high blood pressure and heart failure

Vertex Receives Australia Approval for Symdeko to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations

IMV Underwriters Buy Additional 504,855 Common Shares in Offering

EC approves marketing authorisation for Roche's Tecentriq in combination with Avastin and chemotherapy

Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis